No. Briviact (brivaracetam) is not classified as a controlled substance under the U.S. Controlled Substances Act, so it carries no DEA schedule, no narcotic restrictions, and no federal tracking requirement. It is a prescription-only anticonvulsant that the FDA approved in May 2016 for partial-onset seizures in people with epilepsy. You might panic at the word “prescription,” assuming it means “controlled,” and worry unnecessarily about addiction or refill hassles that simply do not apply to your situation.
The sections below cover why Briviact escaped scheduling, how it compares to clonazepam or pregabalin, and what that non-controlled status means for your refills, travel, and pharmacy transfers.
The Short Answer on Briviact’s Legal Status
Federal regulators do not list Briviact in any DEA schedule, so pharmacists treat it like a routine prescription rather than a controlled narcotic. The FDA approved it in 2016 as an adjunct therapy for partial-onset seizures, and the agency never flagged it for abuse potential during review. That keeps Briviact in the same legal bucket as most blood pressure drugs or antibiotics: a doctor must authorize it, but the government does not track every pill that leaves the pharmacy.
Much of the confusion around this topic traces back to a single mix-up. “Rx-only” gets mentally collapsed into “controlled,” even though the two categories live in different parts of federal law. Prescription-only means a licensed prescriber must authorize dispensing. Controlled means the DEA places it in one of five schedules because of recognized abuse or dependence risk. Briviact sits in the first category, not the second.
Tip: When you pick up Briviact, you sign for a regular prescription, not the double-counted narcotic receipt that pharmacies use for oxycodone or alprazolam. That small detail at the counter reflects a much larger legal distinction.
Quick reference points on Briviact’s legal status:
- No DEA schedule: Briviact is absent from the DEA’s list of scheduled chemicals, so it is treated as a non-controlled prescription at the federal level.
- FDA-approved in May 2016: UCB, a Belgian pharmaceutical company, brought Briviact to market as an adjunct therapy for partial-onset seizures in patients age 16 and older.
- Rx-only, not narcotic: You need a prescription, but the drug carries none of the refill caps, lock-in programs, or DEA Form 222 paperwork tied to scheduled drugs.
- No euphoria signal: Clinical studies and post-market data have not surfaced the reward effects that would trigger scheduling.
How the DEA Decides Which Drugs Get Scheduled
The Controlled Substances Act creates five schedules (I through V) and places each drug based on three factors: medical use, abuse potential, and dependence risk. Schedule I covers drugs with no accepted medical use and high abuse potential, such as heroin or LSD. Schedules II through V move progressively toward accepted medical use and progressively lower abuse potential. The DEA reviews new drugs, sometimes at the FDA’s request, and decides whether the evidence justifies placement.
Federal reviewers weigh clinical trial data, real-world safety reports, and chemical similarity to known controlled substances. They also look at whether the drug crosses the blood-brain barrier in ways that produce euphoria or withdrawal. Brivaracetam passed this review without showing the dopamine-driven reward signal that would have raised scheduling concerns. That is why a search of the DEA Diversion Control pages produces no entry for the drug, and why your prescription experience stays simple.
The Eight Factors Behind Every Scheduling Decision
Federal statute lays out the exact criteria the DEA applies. Understanding them explains why two anticonvulsants with similar uses can land in completely different legal categories.
- Actual or relative potential for abuse: Reviewed through clinical trials, animal studies, and post-market surveillance.
- Scientific evidence of pharmacological effect: Whether the molecule acts on the brain in ways that could drive compulsive use.
- Current scientific knowledge: Including whether the chemical structure resembles known drugs of abuse.
- History and pattern of abuse: Tracked through poison control centers, emergency room data, and law enforcement reports.
- Scope, duration, and significance of abuse: How widespread any problem has become.
- Risk to public health: Whether diversion would create measurable community harm.
- Psychic or physiological dependence liability: Whether users build tolerance or face withdrawal.
- Immediate precursor relationship to a controlled substance: Whether the drug can be easily converted into something scheduled.
Tip: Brivaracetam is a racetam derivative, chemically related to levetiracetam (Keppra), which has been a non-controlled anticonvulsant for decades. That family resemblance gave reviewers a useful comparison point during evaluation and helps explain why your refill workflow resembles Keppra’s rather than a benzodiazepine’s.
Why Prescription-Only Is Not the Same as Controlled
Federal law treats these as separate classifications that often overlap in public perception but live in different regulatory boxes. Prescription-only status means a state-licensed prescriber must authorize the medication. Controlled status means the DEA has placed the drug into a schedule and pharmacies must track it with extra paperwork, storage rules, and refill restrictions. Many heavily prescribed medications sit in the first bucket without ever crossing into the second.
This distinction protects you from worrying that every prescription carries addiction risk. Common blood pressure drugs, statins, most antibiotics, and insulin all require a prescription yet remain completely outside the DEA’s scheduling system. Briviact sits in that same non-controlled, prescription-only category, so your pharmacy visit should feel no different from picking up a cholesterol medication.
A Side-by-Side Comparison
| Feature | Prescription-Only (Briviact) | Controlled Substance (e.g., alprazolam) |
|---|---|---|
| Requires a doctor’s prescription | Yes | Yes |
| Listed on a DEA schedule | No | Yes (Schedule IV for alprazolam) |
| DEA Form 222 required | No | Yes for Schedule II |
| Refill limits per prescription | Up to 12 months of refills allowed | 0–5 refills depending on schedule |
| State PDMP reporting | Rare | Standard |
| Triplicate prescription forms (legacy) | No | Yes in some states |
The table makes the legal gap visible at a glance. Two medications can require the same kind of doctor visit yet trigger completely different pharmacy procedures, and Briviact lives on the simpler side of that line.
Where Briviact Sits Among Other Seizure Medications
Epilepsy treatment includes a wide range of anticonvulsants, and their legal classifications vary dramatically. Comparing Briviact to commonly prescribed seizure drugs reveals just how unusual its non-controlled status really is.
Clonazepam (Klonopin) is a benzodiazepine that the DEA controls because of its well-documented sedation, dependence, and withdrawal risks. Phenobarbital, one of the oldest barbiturate anticonvulsants, sits in Schedule IV for similar reasons. Pregabalin (Lyrica) earned a Schedule V listing in 2020 after post-market data revealed growing misuse. Brivaracetam shares a therapeutic purpose with these drugs yet occupies a completely different regulatory position, and that gap shows up clearly at your pharmacy counter.
How Common Anticonvulsants Are Scheduled
| Drug (Brand Name) | Drug Class | DEA Schedule |
|---|---|---|
| Brivaracetam (Briviact) | Racetam derivative | None |
| Levetiracetam (Keppra) | Pyrrolidine derivative | None |
| Pregabalin (Lyrica) | Gabapentinoid | Schedule V |
| Clonazepam (Klonopin) | Benzodiazepine | Schedule IV |
| Phenobarbital | Barbiturate | Schedule IV |
| Diazepam (Valium) | Benzodiazepine | Schedule IV |
That contrast matters in everyday pharmacy encounters. A patient picking up Briviact and clonazepam on the same day will notice different procedures: one receipt is a routine prescription, the other often requires a signature, a count, and possibly a state database lookup. Both drugs treat seizure disorders, yet only one triggers the heavier workflow.
- Schedule V (pregabalin): Limited refills, prescriber DEA number required, some states mandate PDMP checks.
- Schedule IV (clonazepam, phenobarbital): Five refills within six months maximum, and prescriptions expire after six months in many states.
- Non-controlled (brivaracetam, levetiracetam): Twelve-month refills allowed, prescription valid for one full year from the written date in most states.
Practical Effects on Refills, Travel, and Pharmacy Use
Because Briviact is not scheduled, your refill, travel, and pharmacy transfer experiences follow standard prescription rules rather than the stricter controlled-substance workflow. That difference shows up in several concrete ways that you will notice almost immediately.
A neurologist can write Briviact with up to 12 refills good for a full year, while a clonazepam prescription caps out at five refills within six months. Crossing state lines with Briviact does not raise the kind of questions that travelers face when carrying oxycodone or even pregabalin in some jurisdictions. Pharmacy transfers between states generally require only a standard prescription transfer call, not the documentation that scheduled drugs often demand.
Refill Timing and Doctor Visits
Standard 12-month refills are allowed without the trip limits that apply to Schedule II drugs, and most insurers will cover that full course. Your prescribing neurologist typically sees you once every three to six months rather than monthly, because the prescription itself does not force tight visit cycles. If you move or switch insurance, the prescription remains valid until its expiration date.
TSA Screening and Domestic Travel
TSA screening recognizes Briviact as a routine prescription, not a controlled narcotic, so you can pack tablets or oral solution through security in their original labeled pharmacy bottle. Injectable formulations require a slightly different setup (cooler packs and documentation if refrigeration is needed), but no special travel letter is mandated by federal authority. International travel introduces a separate set of country-specific rules, so a quick check of the destination’s medication import policy is still smart before you fly.
Pharmacy Transfers Across State Lines
Most cross-state pharmacy transfers proceed under standard prescription rules, with no additional controlled-substance paperwork required. A pharmacist in your new state can usually call the old pharmacy, transfer the remaining refills, and fill the prescription on the spot. Controlled drugs often require a new prescription from a local prescriber; Briviact does not.
State Prescription Drug Monitoring Programs
State PDMPs generally do not flag Briviact because reporting requirements focus on scheduled substances. A small number of states track additional drugs of concern, so it is worth confirming with your pharmacist if you live in one of those jurisdictions. The DEA also keeps a current scheduling list at its Diversion Control site, which can confirm in seconds whether anything has changed.
Tip: A short phone call to your state’s board of pharmacy answers any PDMP-specific question in under five minutes. Ask whether brivaracetam appears on your state’s monitored drug list, because rules vary.
How to Verify Briviact’s Status Yourself
Three authoritative sources let you confirm Briviact’s non-controlled status in just a few minutes. These checks take only a few minutes and remove any remaining doubt about the drug’s legal category.
The FDA prescribing information PDF lists no controlled substance warning in its boxed or warning sections, and the document specifies that Briviact is a prescription-only anticonvulsant. The DEA’s scheduling list and Diversion Control pages contain no entry for brivaracetam, which is the fastest confirmation possible. The FDA Orange Book confirms Briviact’s prescription status and lists therapeutic equivalence data for generic formulations. Asking a pharmacist or epilepsy specialist provides a real-time confirmation for any state-specific concerns that federal sources cannot address.
Three Reliable Sources to Check
- FDA Prescribing Information PDF: Available on the FDA website, this document carries the official labeling and includes no scheduling box. Search for “brivaracetam” on the FDA’s drug label database.
- DEA Diversion Control Drug Schedules: The DEA publishes complete scheduling lists online at deadiversion.usdoj.gov. A search for “brivaracetam” returns no results, which is the answer you want.
- FDA Orange Book: Lists approved drug products with therapeutic equivalence evaluations. Briviact appears under brivaracetam with no controlled substance flag.
Questions to Ask Your Pharmacist or Neurologist
Real-time confirmation from a healthcare professional is sometimes the fastest route, especially when state-specific rules are in play. Bring these questions to your next visit.
- Most states say no, but a handful of programs track additional drugs.
- Non-controlled status does not affect insurance coverage rules, but plans vary.
- Federal law allows it, and most states honor that.
- A printed label or summary can speed up customs questions abroad.
Bottom Line
Briviact is not a controlled substance. It is a prescription-only anticonvulsant that the FDA approved in 2016 and the DEA has never scheduled, leaving it free of the refill caps, paperwork, and tracking that govern drugs like clonazepam or pregabalin. For patients managing partial-onset seizures, that legal status means simpler pharmacy visits, easier cross-state transfers, and no federal signal that the medication carries addiction risk, though any concerns about side effects or dependence should still go to the neurologist who prescribes it.
FAQ
Is Briviact classified as a controlled substance?
No. The DEA does not list brivaracetam in any of its five schedules, so Briviact is treated as a non-controlled prescription under federal law. Only the FDA’s prescription requirement applies to you at the federal level.
What schedule is Briviact under?
No DEA schedule currently applies to Briviact, placing it outside the federal controlled-substance classification system. It carries no schedule number and no controlled substance warning on its FDA-approved labeling. You can verify this against the Diversion Control drug schedule list at any time.
Does Briviact have abuse potential?
Clinical studies and post-market data have not surfaced the reward or compulsive-use signals that would trigger scheduling. Common side effects include drowsiness, dizziness, fatigue, and nausea, but no euphoric or addictive effects are documented in the FDA label.
Is Briviact addictive?
Brivaracetam has no recognized addiction or dependence liability in federal review or in the FDA prescribing information. If you stop the drug, you should still taper under medical supervision, but the concern is seizure control, not withdrawal.
Why is Briviact not a controlled substance?
It cleared the DEA’s eight-factor review without showing abuse potential, dependence risk, or chemical resemblance to scheduled drugs. Its racetam structure and similarity to levetiracetam (Keppra), another non-controlled anticonvulsant, supported that conclusion.
Can you get a prescription for Briviact without special requirements?
Yes. A standard prescription from a licensed prescriber is sufficient, and no DEA triplicate forms, special pads, or extra paperwork are needed. Insurance prior authorization rules may still apply, but those are separate from controlled-substance requirements.
